A rebuttal letter to the letter ID number CLRH-D-۲۱-۰۰,۸۳۶ entitled "On the efficacy and safety of rituximab therapy in patients withsystemic sclerosis disease: missing points, bottlenecks, over-exaggeration and discrepancies(Clin Rheumatol)
۱۴
(Eur Pharmacol)Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells
The expansion of CD۱۴+ CD۱۶۳+ subpopulation of monocytes and myeloid cells-associated cytokine imbalance; candidate diagnostic biomarkers for celiac disease (CD) ( JCLA Journal of Clinical Laboratory Analysis )